These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 16877525)
1. Tumor-specific expression of the RGD-alpha3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice. Miyoshi T; Hirohata S; Ogawa H; Doi M; Obika M; Yonezawa T; Sado Y; Kusachi S; Kyo S; Kondo S; Shiratori Y; Hudson BG; Ninomiya Y FASEB J; 2006 Sep; 20(11):1904-6. PubMed ID: 16877525 [TBL] [Abstract][Full Text] [Related]
2. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. Maeshima Y; Colorado PC; Torre A; Holthaus KA; Grunkemeyer JA; Ericksen MB; Hopfer H; Xiao Y; Stillman IE; Kalluri R J Biol Chem; 2000 Jul; 275(28):21340-8. PubMed ID: 10766752 [TBL] [Abstract][Full Text] [Related]
3. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis. Boosani CS; Mannam AP; Cosgrove D; Silva R; Hodivala-Dilke KM; Keshamouni VG; Sudhakar A Blood; 2007 Aug; 110(4):1168-77. PubMed ID: 17426256 [TBL] [Abstract][Full Text] [Related]
4. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Hamano Y; Kalluri R Biochem Biophys Res Commun; 2005 Jul; 333(2):292-8. PubMed ID: 15979458 [TBL] [Abstract][Full Text] [Related]
5. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713 [TBL] [Abstract][Full Text] [Related]
6. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion. Pedchenko V; Zent R; Hudson BG J Biol Chem; 2004 Jan; 279(4):2772-80. PubMed ID: 14610079 [TBL] [Abstract][Full Text] [Related]
8. Goodpasture antigen: expression of the full-length alpha3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain. Leinonen A; Netzer KO; Boutaud A; Gunwar S; Hudson BG Kidney Int; 1999 Mar; 55(3):926-35. PubMed ID: 10027929 [TBL] [Abstract][Full Text] [Related]
9. The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent. Floquet N; Pasco S; Ramont L; Derreumaux P; Laronze JY; Nuzillard JM; Maquart FX; Alix AJ; Monboisse JC J Biol Chem; 2004 Jan; 279(3):2091-100. PubMed ID: 14583633 [TBL] [Abstract][Full Text] [Related]
10. Evidence for telomerase involvement in the angiogenesis of astrocytic tumors: expression of human telomerase reverse transcriptase messenger RNA by vascular endothelial cells. Pallini R; Pierconti F; Falchetti ML; D'Arcangelo D; Fernandez E; Maira G; D'Ambrosio E; Larocca LM J Neurosurg; 2001 Jun; 94(6):961-71. PubMed ID: 11409526 [TBL] [Abstract][Full Text] [Related]
11. [Reconstruction of adenovirus vector contained canstatin gene and hTERT gene core promoter and its anti-tumor effect in human ovarian cancer]. Zhu BJ; Qiao YH; Li Y Zhonghua Fu Chan Ke Za Zhi; 2009 Mar; 44(3):214-8. PubMed ID: 19570449 [TBL] [Abstract][Full Text] [Related]
12. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma]. Song Y; Shen K; Yu JR Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307 [TBL] [Abstract][Full Text] [Related]
13. Selective binding of integrins from different renal cell types to the NC1 domain of alpha3 and alpha1 chains of type IV collagen. Aggeli AS; Kitsiou PV; Tzinia AK; Boutaud A; Hudson BG; Tsilibary EC J Nephrol; 2009; 22(1):130-6. PubMed ID: 19229828 [TBL] [Abstract][Full Text] [Related]
14. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624 [TBL] [Abstract][Full Text] [Related]
16. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells. He GA; Luo JX; Zhang TY; Hu ZS; Wang FY Biochem Biophys Res Commun; 2004 May; 318(2):354-60. PubMed ID: 15120609 [TBL] [Abstract][Full Text] [Related]
17. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. MacKenzie KL; Franco S; Naiyer AJ; May C; Sadelain M; Rafii S; Moore MA Oncogene; 2002 Jun; 21(27):4200-11. PubMed ID: 12082607 [TBL] [Abstract][Full Text] [Related]
18. [Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter]. Jacob D; Davis J; Schumacher G; Bahra M; Neuhaus P; Fang B Z Gastroenterol; 2004 Dec; 42(12):1363-70. PubMed ID: 15592959 [TBL] [Abstract][Full Text] [Related]
19. Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. Roth JM; Akalu A; Zelmanovich A; Policarpio D; Ng B; MacDonald S; Formenti S; Liebes L; Brooks PC Am J Pathol; 2005 Mar; 166(3):901-11. PubMed ID: 15743801 [TBL] [Abstract][Full Text] [Related]
20. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Murasawa S; Llevadot J; Silver M; Isner JM; Losordo DW; Asahara T Circulation; 2002 Aug; 106(9):1133-9. PubMed ID: 12196341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]